Eagle Pharmaceuticals, Inc.
OTCPK:EGRX Voorraadrapport
Marktkapitalisatie: US$11.1m
Eagle Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6 Eagle Pharmaceuticals heeft een totaal eigen vermogen van $252.0M en een totale schuld van $70.2M, wat de schuld-eigenvermogensverhouding op 27.8% brengt. De totale activa en totale passiva bedragen respectievelijk $404.8M en $152.8M. De EBIT Eagle Pharmaceuticals is $41.7M waardoor de rentedekking 7.2 is. Het heeft contanten en kortetermijnbeleggingen van $15.4M.
Belangrijke informatie
27.8%
Verhouding schuld/eigen vermogen
Rente dekkingsratio 7.2x Contant US$15.35m Aandelen US$252.04m Totaal verplichtingen US$152.78m Totaal activa US$404.82m
Recente financiële gezondheidsupdates Hearings Panel of The Nasdaq Stock Market LLC Determines to Delist Eagle Pharmaceuticals' Common Stock from Nasdaq Oct 04
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq Aug 28 Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing Aug 10
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq May 23 Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing May 12
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K Apr 13
Toon alle updates
Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes Nov 12 Hearings Panel of The Nasdaq Stock Market LLC Determines to Delist Eagle Pharmaceuticals' Common Stock from Nasdaq Oct 04
Eagle Pharmaceuticals, Inc.(OTCPK:EGRX) dropped from NASDAQ Composite Index
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq Aug 28 Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing Aug 10
Eagle Pharmaceuticals, Inc. and Curia Global, Inc. Enters into Settlement Agreement in AAA Case No. 01-23-0000-2937 Jul 10 Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Index
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq May 23 Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing May 12
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K Apr 13 Eagle Pharmaceuticals, Inc. announced delayed annual 10-K filing Mar 19
Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes
New minor risk - Financial data availability Feb 24
Investor sentiment improves as stock rises 19% Feb 21
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Eagle Pharmaceuticals, Inc Dec 12 Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer
Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing Nov 11
Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 10
Investor sentiment deteriorates as stock falls 32% Nov 10
Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 09
Founder notifies of intention to sell stock Nov 03
Centers for Medicare & Medicaid Services Establishes Unique, Product-Specific Billing Code and Grants Transitional Pass-Through Payment Status for Barhemsys (Amisulpride) Injection by Eagle Pharmaceuticals, Inc Oct 24
Founder notifies of intention to sell stock Oct 04
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment? Sep 21
Investor sentiment deteriorates as stock falls 18% Aug 15
New major risk - Revenue and earnings growth Aug 09
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 08
Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Eagle Pharmaceuticals, Inc. Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, A Novel First-In-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia Jul 25
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Jul 13
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Growth-Defensive Index Jun 25
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly Jun 21
New major risk - Revenue and earnings growth Jun 17
Eagle Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (Qidp) and Fast-Track Designation for Cal02, Providing Five-Year Exclusivity Extension Jun 15
Founder recently sold US$931k worth of stock May 17
Founder notifies of intention to sell stock May 15
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 14
Consensus EPS estimates fall by 20% Jan 25
Eagle Pharmaceuticals, Inc. Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy Dec 20
Consensus forecasts updated Nov 23
Insufficient new directors Nov 16
Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia Nov 15
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 08
Eagle Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Nov 01
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely Oct 27
Eagle Pharmaceuticals, Inc Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02 Oct 14
Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia Oct 12
Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose Sep 27
Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders. Sep 17
Independent Director recently sold US$211k worth of stock Sep 09
Insufficient new directors Sep 02
U.S. Court of Appeals for the Federal Circuit Affirms the U.S. District Court for the District of Delaware’s Decision That Eagle Pharmaceuticals, Inc.'s Vasopressin Product Does Not Infringe on Any of the Patents Asserted by Par Pharmaceutical, Inc Aug 19
Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court Aug 18
Consensus revenue estimates fall by 21% Aug 16
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be Aug 15
Price target decreased to US$43.00 Aug 10
Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M Aug 09
Eagle Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 29 Michael Moran Separates as Executive Vice President, Chief Commercial Officer of Eagle Pharmaceuticals, Inc
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely Jul 06
Eagle Pharmaceuticals, Inc., Annual General Meeting, Jul 28, 2022 Jun 16
Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) completed the acquisition of Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders. Jun 10
Eagle Pharmaceuticals, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, A Beta-1 Adrenergic Blocker Jun 02
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 10
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price Apr 29
Now 20% undervalued Apr 19
Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders for €89.8 million. Mar 30
Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH). Mar 29
Eagle Pharmaceuticals, Inc. Provides Earnings Guidance for the First Quarter of 2022 Mar 10
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 09
Eagle Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 07, 2022 Feb 25
Eagle Pharmaceuticals, Inc. Announces Commercial Availability of PEMFEXY™ Feb 02
Eagle Pharmaceuticals, Inc. on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker Feb 01
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin Jan 19
Eagle Pharmaceuticals, Inc. Receives 180 Days of Marketing Exclusivity for Approved Vasopressin Dec 30
Eagle Pharmaceuticals, Inc. Receives FDA Approval for Vasopressin Dec 16
Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt? Dec 16
Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.52 profit in 3Q 2020) Nov 11
Price target increased to US$50.50 Nov 11
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $187.3M ) EGRX } overtreffen de korte termijn passiva ( $86.6M ).
Langlopende schulden: De kortetermijnactiva EGRX ( $187.3M ) overtreffen de langetermijnschulden ( $66.2M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 21.8% ) EGRX wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van EGRX is de afgelopen 5 jaar gestegen van 25.2% naar 27.8%.
Schuldendekking: De operationele kasstroom van EGRX is negatief, waardoor de schuld niet goed gedekt is.
Rentedekking: De rentebetalingen op de schuld van EGRX worden goed gedekt door EBIT ( 7.2 x dekking).
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
